SCHEMBL2357585

SCHEMBL2357585

N#Cc1cccc(NC(=O)C(ON=C2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)C(ON=C2CCN(S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)(C(N)=O)c2cccc(F)c2)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TSHR P16473 1/20 0.37
MAPT P10636 3/20 0.37
XBP1 P17861 1/20 0.37
HTT P42858 1/20 0.37
IDH2 P48735 5/20 0.37
LMNA P02545 5/20 0.37
ALDH1A1 P00352 1/20 0.37
HSD17B10 Q99714 1/20 0.37
EPHX2 P34913 2/20 0.36
SCN9A Q15858 2/20 0.36
RHOA P61586 1/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
HIF1A Q16665 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2357582 0.79 KMT2A (0.48) MEN1KMT2ATSHRMAPTXBP1
SCHEMBL2357586 0.79 KMT2A (0.41) MEN1KMT2ATSHRMAPTXBP1
SCHEMBL2298258 0.76 KMT2A (0.51) MEN1KMT2ATSHRMAPTXBP1
SCHEMBL2292202 0.75 MEN1 (0.50) MEN1KMT2ATSHRMAPTXBP1
SCHEMBL2294491 0.73 EPHX2 (0.45) MEN1KMT2AMAPTHTTLMNA
SCHEMBL2295416 0.71 KMT2A (0.54) MEN1KMT2ATSHRMAPTXBP1
SCHEMBL2297370 0.70 ALDH1A1 (0.53) MEN1KMT2ATSHRMAPTLMNA
SCHEMBL2292379 0.69 TSHR (0.50) MEN1KMT2ATSHRMAPTXBP1
SCHEMBL2291074 0.69 LMNA (0.53) MEN1KMT2AMAPTHTTLMNA
SCHEMBL2293229 0.69 SCN9A (0.49) MEN1KMT2AHTTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S MEN1 3484/4885KMT2A 2564/4885TSHR 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.